In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alfasigma S.p.A.

http://www.alfasigma.com/en

Latest From Alfasigma S.p.A.

Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs

Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.

Deal Watch Business Strategies

Travere’s Sparsentan Faces Slower Uptake Due To Liver Monitoring Requirement

The FDA required an updated REMS for liver monitoring out of caution over potential liver toxicity, though the drug has not caused drug-induced liver injury in development to date.

Business Strategies Renal

Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C

Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals. 

Financing Innovation

Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely

Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.

Renal Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • ALFASIGMA
    • Defiante Farmaceutica S.A.
    • Sigma-Tau Pharma Ltd
    • Sigma-Tau Arzneimittel GmbH
    • Sigma-Tau Research Switzerland SA
    • Biofutura Pharma S.p.A.
    • Alfa Wassermann SpA
UsernamePublicRestriction

Register